Found 554 articles
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Vera Therapeutics, Inc. today reported its business highlights for the fourth quarter and financial results for the full year ended December 31, 2022.
Incyte Provides Regulatory Update on Ruxolitinib Extended-Release Tablets
Incyte announced that the U.S. Food and Drug Administration has issued a complete response letter for ruxolitinib extended-release tablets, a JAK1/JAK2 inhibitor, for once-daily use in the treatment of certain types of myelofibrosis, polycythemia vera and graft-versus-host disease.
Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results
Marker Therapeutics, Inc. today reported fiscal year 2022 financial results and provided updates for its clinical development programs.
Protagonist Therapeutics Announces Highly Statistically Significant Results from the Randomized Withdrawal Portion of the REVIVE Study of Rusfertide in Polycythemia Vera
Protagonist Therapeutics, Inc. today announced positive topline results from the blinded, placebo-controlled, randomized withdrawal portion of REVIVE achieved highly statistically significant improvements versus placebo in the primary endpoint.
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
Silence Therapeutics plc today reported its financial results for the fourth quarter and full year ended December 31, 2022 and reviewed recent business highlights.
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
Protagonist Therapeutics reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.
Mabwell Launched First in human Clinical Trial of Its Iron Homeostasis Regulating Macromolecular Drug 9MW3011
Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, launched first in human clinical trial of its iron homeostasis regulating macromolecular drug 9MW3011.
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Incyte (Nasdaq:INCY) today announced that multiple abstracts from across its oncology portfolio will be presented during the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, held April 14-19, in Orlando, Florida.
Protagonist Therapeutics Announces Positive Topline Results for Phase 2b FRONTIER 1 Clinical Trial of Oral IL-23 Receptor Antagonist JNJ-2113 (PN-235) in Psoriasis
Protagonist Therapeutics, Inc. today announced positive topline results from its collaboration with Janssen Biotech, Inc. in the FRONTIER 1 Phase 2b clinical trial evaluating the oral Interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 in patients with moderate-to-severe plaque psoriasis.
Multiple Abstracts from Incyte’s Growing Dermatology Portfolio Featured at American Academy of Dermatology (AAD) Annual Meeting
Incyte announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming 2023 American Academy of Dermatology Annual Meeting, held March 17-21, 2023, in New Orleans.
Vera Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that the Company’s management team will participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, which is taking place in Boston, MA from March 6 – 8, 2023.
PharmaEssentia Initiates Phase 2b Trial of ropeginterferon alfa-2b-njft for Essential Thrombocythemia (ET) in North America
PharmaEssentia today announced that the first patients are now being dosed in a Phase 2b clinical study evaluating ropeginterferon alfa-2b-njft for the treatment of adults with essential thrombocythemia (ET).
The FDA granted accelerated approval Friday to Travere Therapeutics’ sparsentan, now to be marketed as Filspari, to reduce the burden of proteinuria in adults with primary IgA nephropathy.
Disc Medicine Announces $62.5 Million Financing led by Bain Capital Life Sciences to Advance Portfolio of Novel Hematology Programs
Disc Medicine, Inc. (NASDAQ: IRON) a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced it has entered into a securities purchase agreement with certain investors resulting in an aggregate $62.5 million in gross proceeds through a registered direct offering.
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs.
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
Vera Therapeutics, Inc. (NasdaqGM: VERA; “Vera”) today announced the closing of its previously announced underwritten public offering of 16,428,572 shares of its Class A common stock, including the exercise in full by the underwriters of their option to purchase an additional 2,142,857 shares, at a price to the public of $7.00 per share.
Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera
PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the publication of a review of clinical literature in the journal, Frontiers in Oncology.
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock - February 02, 2023
Vera Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 14,285,715 shares of its Class A common stock at a price to the public of $7.00 per share.
Ratio Therapeutics Announces $20M Series A Financing to Advance Targeted Radiotherapies for Cancer Treatment
Ratio Therapeutics Inc. announces the close of its Series A financing extension today, bringing the total raised to date to over $40 million.
Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock - Feb 01, 2023
Vera Therapeutics, Inc. announced that it has commenced a public offering, subject to market and other conditions, to issue and sell $75.0 million of shares of its Class A common stock.